mek inhibitor + hydroxychloroquine + bevacizumab

This is a combination therapy consisting of three agents: - A MEK inhibitor (a class of small molecule drugs that inhibit mitogen-activated protein kinase kinases, commonly used in cancer therapy to block the MAPK/ERK pathway), - Hydroxychloroquine (an antimalarial and immunomodulatory agent that inhibits autophagy by blocking lysosomal acidification), - Bevacizumab (a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor, VEGF, thereby inhibiting angiogenesis)[3][4][5]. The rationale for this combination is typically to target cancer cells through multiple mechanisms: - The MEK inhibitor blocks cell proliferation signaling. - Hydroxychloroquine impairs autophagy, a survival mechanism often upregulated in tumor cells under stress from targeted therapies. - Bevacizumab inhibits tumor angiogenesis by neutralizing VEGF[3][4][5]. This regimen has been explored in clinical trials for various solid tumors, particularly those resistant to standard therapies.

Brand names

PlaquenilAvastinMekinistCotellicMektovi

Other names

MEK inhibitor + hydroxychloroquine ± bevacizumabMEK inhibitor + hydroxychloroquine combination therapy